An Update on Mail Service: April 27, 2020
The Benefit Fund Office is committed to prioritizing all of our services to plan participants, despite the current times. We want to inform you that the Fund is currently experiencing delays in mail receipt. The mail that has been received by the Benefit Fund Office has been significantly lower than our normal volume. Please note, that any participant or employer mail that has been sent to the Benefit Fund Office is likely to be delayed, leading to additional delays in processing. We appreciate your continued patience during this unprecedented time. We are working diligently to ensure that all participants and beneficiaries whom are currently receiving benefits, will continue to do so.
At the Benefit Funds Office (BFO) we believe in being proactive and transparent in addressing issues, and we value information alongside clear communication.
With this in mind, we have temporarily closed our physical office due to coronavirus (COVID-19) exposure.
Our office will be completely closed until the end of next week as we take additional precautionary measures, but we are continuing to work remotely to the best of our abilities.
We appreciate your continued patience and understanding as this will impact some of our services. For further questions please contact our Customer Service Department at 1-800-457-3481, Monday - Friday, 8:30 a.m. to 4:00 p.m. Eastern Time.
Coverage of COVID-19 Testing and Treatment/Cost Sharing Waiver
Effective immediately, the Board of Trustees of the National IAM Benefit Trust Fund have implemented the following cost-sharing changes related to COVID-19 testing and treatment through May 31, 2020.
Cost-sharing is the portion of the testing and/or treatment that the plan participant would normally pay out of pocket, such as co-payments and co-insurance. The Fund’s medical network and claims payment vendor, Cigna, has been notified of this decision and will process cost-sharing accordingly.
• Waiving cost-sharing for the COVID-19 diagnostic test when recommended by a health care professional
• Waiving cost-sharing for office visits related to COVID-19 testing
• Waiving cost-sharing for telehealth screenings for COVID-19
• Waiving customer cost-sharing for all COVID-19 treatment
• Making it easier for participants to be treated virtually by their own physicians
• Offering a 24-hour COVID-19 toll-free helpline at 1-866-912-1687. This helpline is available to allow you to speak with behavioral health clinicians who can provide one-on-one support
Please take all required and necessary preventative measures to help reduce the spread of COVID-19 and stay safe.
Due to the office closure, all disability payments are delayed.
During the closure, you may still contact the following vendors via telephone or use their website to learn more about your benefits. Participants can request insurance cards, verify benefits and ask questions about claims.
• Cigna Phone: 800-244-6224 Website: www.mycigna.com
• CVS Caremark Phone: 866-282-8503 Website: www.caremark.com
• Delta Dental Phone: 800-521-2651 Website: www.deltadentalins.com
• EyeMed Phone: 866-723-0513 Website: www.eyemed.comm
Our Customer Service phone lines will not be operational during the office closure. Please continue to monitor our websites for updates. The Benefit Fund Office will respond to emails regarding urgent health concerns that require emergency care; if an illness is not treated immediately, the participant’s condition would result in disability or death. If you have an urgent health care concern, please send secure messages to firstname.lastname@example.org.
Employers must continue to remit payment by the last day of each month. Payments made via lockbox should continue to be sent to National IAM Benefit Trust Fund P.O. Box 64607, Baltimore, MD 21279-4607.
During the office closure, our Education Team will still be available to assist you. Please contact your territory’s Pension Coordinator if you require assistance to identify the appropriate Education Representative
Please click here for more information about COVID-19.